These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 20110785

  • 21. Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies.
    Zhu AX, Duda DG, Sahani DV, Jain RK.
    Cancer J; 2009; 15(4):263-8. PubMed ID: 19672141
    [Abstract] [Full Text] [Related]

  • 22. Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux.
    Giuliano S, Cormerais Y, Dufies M, Grépin R, Colosetti P, Belaid A, Parola J, Martin A, Lacas-Gervais S, Mazure NM, Benhida R, Auberger P, Mograbi B, Pagès G.
    Autophagy; 2015; 11(10):1891-904. PubMed ID: 26312386
    [Abstract] [Full Text] [Related]

  • 23. Biomarkers to predict response to sunitinib therapy and prognosis in metastatic renal cell cancer.
    Yuasa T, Takahashi S, Hatake K, Yonese J, Fukui I.
    Cancer Sci; 2011 Nov; 102(11):1949-57. PubMed ID: 21812860
    [Abstract] [Full Text] [Related]

  • 24. Sunitinib: new drug. For some gastrointestinal stromal tumours.
    Prescrire Int; 2007 Aug; 16(90):138-41. PubMed ID: 17724833
    [Abstract] [Full Text] [Related]

  • 25. Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma.
    Bridgeman VL, Wan E, Foo S, Nathan MR, Welti JC, Frentzas S, Vermeulen PB, Preece N, Springer CJ, Powles T, Nathan PD, Larkin J, Gore M, Vasudev NS, Reynolds AR.
    Mol Cancer Ther; 2016 Jan; 15(1):172-83. PubMed ID: 26487278
    [Abstract] [Full Text] [Related]

  • 26. MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model.
    Diaz-Montero CM, Mao FJ, Barnard J, Parker Y, Zamanian-Daryoush M, Pink JJ, Finke JH, Rini BI, Lindner DJ.
    Br J Cancer; 2016 Oct 11; 115(8):920-928. PubMed ID: 27560553
    [Abstract] [Full Text] [Related]

  • 27. Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor.
    Roskoski R.
    Biochem Biophys Res Commun; 2007 May 04; 356(2):323-8. PubMed ID: 17367763
    [Abstract] [Full Text] [Related]

  • 28. [Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].
    Török S, Döme B.
    Magy Onkol; 2012 Mar 04; 56(1):3-15. PubMed ID: 22403757
    [Abstract] [Full Text] [Related]

  • 29. Resistance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives.
    Joosten SC, Hamming L, Soetekouw PM, Aarts MJ, Veeck J, van Engeland M, Tjan-Heijnen VC.
    Biochim Biophys Acta; 2015 Jan 04; 1855(1):1-16. PubMed ID: 25446042
    [Abstract] [Full Text] [Related]

  • 30. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.
    Cancer Res; 2003 Sep 15; 63(18):5978-91. PubMed ID: 14522925
    [Abstract] [Full Text] [Related]

  • 31. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
    Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M, Schlessinger J, Ullrich A, Hubbard SR, Blake RA, Fong TA, Strawn LM, Sun L, Tang C, Hawtin R, Tang F, Shenoy N, Hirth KP, McMahon G, Cherrington.
    Cancer Res; 2000 Aug 01; 60(15):4152-60. PubMed ID: 10945623
    [Abstract] [Full Text] [Related]

  • 32. [Angiogenesis and renal cell carcinoma].
    Billemont B, Méric JB, Izzedine H, Taillade L, Sultan-Amar V, Rixe O.
    Bull Cancer; 2007 Jul 01; 94 Spec No():S232-40. PubMed ID: 17846009
    [Abstract] [Full Text] [Related]

  • 33. Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development.
    Sablin MP, Dreyer C, Colichi C, Bouattour M, Delbaldo C, Faivre S, Raymond E.
    Expert Opin Drug Metab Toxicol; 2010 Aug 01; 6(8):1005-15. PubMed ID: 20636223
    [Abstract] [Full Text] [Related]

  • 34. Sunitinib as a paradigm for tyrosine kinase inhibitor development for renal cell carcinoma.
    Lee CH, Motzer RJ.
    Urol Oncol; 2015 Jun 01; 33(6):275-9. PubMed ID: 25465298
    [Abstract] [Full Text] [Related]

  • 35. EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming.
    Adelaiye-Ogala R, Budka J, Damayanti NP, Arrington J, Ferris M, Hsu CC, Chintala S, Orillion A, Miles KM, Shen L, Elbanna M, Ciamporcero E, Arisa S, Pettazzoni P, Draetta GF, Seshadri M, Hancock B, Radovich M, Kota J, Buck M, Keilhack H, McCarthy BP, Persohn SA, Territo PR, Zang Y, Irudayaraj J, Tao WA, Hollenhorst P, Pili R.
    Cancer Res; 2017 Dec 01; 77(23):6651-6666. PubMed ID: 28978636
    [Abstract] [Full Text] [Related]

  • 36. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E, Rösel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch KH, Schneider MR, Drevs J, Martiny-Baron G, Totzke F.
    Cancer Res; 2000 Apr 15; 60(8):2178-89. PubMed ID: 10786682
    [Abstract] [Full Text] [Related]

  • 37. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels.
    Kappers MH, van Esch JH, Sluiter W, Sleijfer S, Danser AH, van den Meiracker AH.
    Hypertension; 2010 Oct 15; 56(4):675-81. PubMed ID: 20733093
    [Abstract] [Full Text] [Related]

  • 38. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma.
    de Boüard S, Herlin P, Christensen JG, Lemoisson E, Gauduchon P, Raymond E, Guillamo JS.
    Neuro Oncol; 2007 Oct 15; 9(4):412-23. PubMed ID: 17622648
    [Abstract] [Full Text] [Related]

  • 39. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
    Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, Hutson TE, Margolin K, Harmon CS, DePrimo SE, Kim ST, Chen I, George DJ.
    J Clin Oncol; 2008 Aug 01; 26(22):3743-8. PubMed ID: 18669461
    [Abstract] [Full Text] [Related]

  • 40. Sunitinib malate.
    Izzedine H, Buhaescu I, Rixe O, Deray G.
    Cancer Chemother Pharmacol; 2007 Aug 01; 60(3):357-64. PubMed ID: 17136543
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.